Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Topic: Angiogenesis and Antiangiogenesis in Hematological Malignancies

A special issue of Journal of Cancer Metastasis and Treatment

ISSN 2454-2857 (Online), ISSN 2394-4722 (Print)

Submission deadline: 31 Dec 2021

Guest Editor(s)

  • Prof. Domenico Ribatti
    Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italy.

    Website | E-mail

Special Issue Introduction

It has been generally accepted that angiogenesis is involved in the pathogenesis of hematological malignancies, like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, and multiple myeloma. The extent of angiogenesis in the bone marrow is correlated with disease burden, prognosis, and treatment outcome. Reciprocal positive and negative interactions between tumor cells and bone marrow stromal cells, namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, endothelial cells, endothelial progenitor cells, T cells, macrophages and mast cells, mediated by an array of cytokines, receptors and adhesion molecules, modulate the angiogenic response in hematological tumors. More recently, the pro-angiogenic role of the so-called “vascular niche” has been emphasized, indicating a site rich in blood vessels where endothelial cells and mural cells such as pericytes and smooth muscle cells create a microenvironment that affects the behavior of several stem and progenitor cells in hematological malignancies.

Anti-angiogenesis was proposed as a cancer therapy over 40 years ago, when Judah Folkman published in the New England Journal of Medicine a hypothesis that tumor growth is angiogenesis-dependent. Several preclinical and clinical trials are exploring the combination of various angiogenesis inhibitors in the treatment of hematological malignancies with other targeted therapies.

The following topics will be discussed in this Special Issue:

The bone marrow microenvironment
Circulating endothelial cells
Endothelial precursor cells
Myeloid derived suppressor cells
Soluble factors and transduction pathways
Exosomes and angiogenesis in MM
Proteasome inhibitors
Receptor tyrosine kinase inhibitors
Monoclonal antibodies
Combination therapies

Submission Deadline

31 Dec 2021

Submission Information

For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Dec 2021
Contacts: Carl Zhou, Assistant Editor,

Published Articles

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties